Initiate the Phase 2 POWER trial of ARD-201
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Aug 2025
- Due
- 31 Dec 2025
- Delivered
- December 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiation of the Phase 2 POWER trial evaluating ARD-201’s potential to prevent weight regain in subjects who discontinue GLP-1RA therapy after achieving substantial prior weight loss (~15%) is expected in the second half of 2025.”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 POWER trial in December 2025, meeting the commitment to begin the trial in the second half of 2025.
-
A Aardvark Therapeutics, Inc. 10-K filed 2026-03-23
“We previously initiated a Phase 2 clinical trial, which we referred to as the POWER (Prevention Of WEight Regain) trial, in December 2025” ✓ confirmed on the page
Market reaction: the shares moved -14.3% against the S&P 500 over the three sessions around the disclosure (20 Mar 2026 to 25 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 13 Aug 2025
Deadline 31 Dec 2025 (“in the second half of 2025”) · target 15 % · wording expected
-
Version 2 · stated 12 Jan 2026
Deadline 30 Jun 2026 (“1H 2026”) · wording expected
“STRENGTH TRIAL Weight Loss ARD-201 ... Expected Initiation 1H 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 POWER trial
- Target
- 15 %
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aardvark Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-AARD-002613 · Corrections policy